Literature DB >> 15063747

Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions.

Stephan Schilling1, Torsten Hoffmann, Susanne Manhart, Matthias Hoffmann, Hans-Ulrich Demuth.   

Abstract

N-terminal pyroglutamate (pGlu) formation from glutaminyl precursors is a posttranslational event in the processing of bioactive neuropeptides such as thyrotropin-releasing hormone and neurotensin during their maturation in the secretory pathway. The reaction is facilitated by glutaminyl cyclase (QC), an enzyme highly abundant in mammalian brain. Here, we describe for the first time that human and papaya QC also catalyze N-terminal glutamate cyclization. Surprisingly, the enzymatic Glu(1) conversion is favored at pH 6.0 while Gln(1) conversion occurs with an optimum at pH 8.0. This unexpected finding might be of importance for deciphering the events leading to deposition of highly toxic pyroglutamyl peptides in amyloidotic diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063747     DOI: 10.1016/S0014-5793(04)00300-X

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  53 in total

1.  Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.

Authors:  Christina Dammers; Kerstin Reiss; Lothar Gremer; Justin Lecher; Tamar Ziehm; Matthias Stoldt; Melanie Schwarten; Dieter Willbold
Journal:  Biophys J       Date:  2017-04-25       Impact factor: 4.033

2.  Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.

Authors:  Jessica L Wittnam; Erik Portelius; Henrik Zetterberg; Mikael K Gustavsson; Stephan Schilling; Birgit Koch; Hans-Ulrich Demuth; Kaj Blennow; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

3.  Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration.

Authors:  Krysti Todd; Silvia Fossati; Jorge Ghiso; Agueda Rostagno
Journal:  Biochim Biophys Acta       Date:  2014-09-28

Review 4.  Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?

Authors:  Julie Dunys; Audrey Valverde; Frédéric Checler
Journal:  J Biol Chem       Date:  2018-08-24       Impact factor: 5.157

Review 5.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

6.  Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.

Authors:  Markus Morawski; Maike Hartlage-Rübsamen; Carsten Jäger; Alexander Waniek; Stephan Schilling; Claudia Schwab; Patrick L McGeer; Thomas Arendt; Hans-Ulrich Demuth; Steffen Rossner
Journal:  Acta Neuropathol       Date:  2010-04-10       Impact factor: 17.088

7.  A gamma-glutamyl transpeptidase-independent pathway of glutathione catabolism to glutamate via 5-oxoproline in Arabidopsis.

Authors:  Naoko Ohkama-Ohtsu; Akira Oikawa; Ping Zhao; Chengbin Xiang; Kazuki Saito; David J Oliver
Journal:  Plant Physiol       Date:  2008-09-03       Impact factor: 8.340

8.  The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42.

Authors:  Gawain McColl; Blaine R Roberts; Adam P Gunn; Keyla A Perez; Deborah J Tew; Colin L Masters; Kevin J Barnham; Robert A Cherny; Ashley I Bush
Journal:  J Biol Chem       Date:  2009-07-02       Impact factor: 5.157

9.  Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Authors:  Oliver Wirths; Tobias Bethge; Andrea Marcello; Anja Harmeier; Sadim Jawhar; Paul J Lucassen; Gerd Multhaup; David L Brody; Thomas Esparza; Martin Ingelsson; Hannu Kalimo; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

10.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.